Contract facts
FederalNo full NAICS 325411 intel page yet. Browse NAICS intelligence
4555923484!GARDASIL 9 SYRINGE 0.5ML is a federal award for Dla Troop Support held by Amerisourcebergen Drug Corp. Estimated value $164K ($164K obligated). Current period of performance ends Jan 13, 2022. Place of performance: CONSHOHOCKEN PA.
Recompete timing
PublicCurrent PoP ended Jan 13, 2022 (1681 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordAmerisourcebergen Drug Corp — $19.3B obligated across 1,357,999 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract SPE2DX22FLBH0?
SPE2DX22FLBH0 (4555923484!gardasil 9 syringe 0.5ml) is a Dla Troop Support award with a potential value of $164K, currently held by Amerisourcebergen Drug Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded SPE2DX22FLBH0?
Dla Troop Support awarded SPE2DX22FLBH0 to Amerisourcebergen Drug Corp (potential $164K).
Who is the incumbent on SPE2DX22FLBH0?
Amerisourcebergen Drug Corp is the incumbent with $19.3B across 1357999 related awards in SCOUT’s public footprint. The current period of performance ends Jan 13, 2022.
When does Amerisourcebergen Drug Corp’s SPE2DX22FLBH0 come up for recompete?
SCOUT tracks a period-of-performance end of Jan 13, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.